Esperion Therapeutics Inc expected to post earnings of 5 cents a share - Earnings Preview

Esperion Therapeutics

03/05/2024 16:18

* Esperion Therapeutics Inc  ESPR.OQ   ESPR.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 7
for the period ending March 31 2024
    * The Vero Beach Florida-based  company is expected to
report a
247.4% increase in revenue to $84.509 million from $24.33
million a year ago, according to the mean estimate from 8
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Esperion Therapeutics
Inc is
for earnings of 5 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 1.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Esperion
Therapeutics Inc is $8.00​, above​ its last closing price
of $2.06. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.41       -0.48      -0.50     Missed  -3.6
 Sep. 30 2023  -0.43       -0.43      -0.37     Beat    14.4
 Jun. 30 2023  -0.62       -0.61      -0.46     Beat    24.8​
 Mar. 31 2023  -0.64       -0.65      -0.79     Missed  -21.1
 ​​Dec.        -0.82       -0.84      -0.76     Beat    9.6
 31 2022                                                
 Sep. 30 2022  -0.92       -0.92      -0.81     Beat    12.4​
 Jun. 30 2022  -0.92       -0.93      -1.05     Missed  -13.4
 Mar. 31 2022  -0.99       -1.04      -0.93     Beat    10.9
 This summary was machine generated May 3 at 15:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)